Create a narrative

Bristol-Myers Squibb Community

NYSE:BMY Community

4 Narratives written by author
0 Comments on narratives written by author
298 Fair Values set on narratives written by author

Create a narrative

Bristol-Myers Squibb

EV

Community Contributor

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.

US$65.00

FV

27.7% undervalued

2.43%

Revenue growth p.a.

3

0

9

3 months ago

Bristol-Myers Squibb

AN

AnalystConsensusTarget

Consensus Narrative from 22 Analysts

Opdivo Pipeline Readouts And Cost Savings Will Secure Future Potential

Key Takeaways Expansion in market acceptance and international approvals of key products drives robust growth, bolstered by promising new indications and oncology programs. Strategic cost efficiency and robust capital allocation efforts enhance financial performance and support sustained earnings growth through 2025.

US$57.20

FV

17.8% undervalued

-4.24%

Revenue growth p.a.

1

0

172

8 days ago